Camp4 Therapeutics Corporation
CAMP
$1.55
-$0.04-2.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.16% | 4.17% | -6.24% | -1.19% | -6.74% |
| Gross Profit | 5.78% | 4.64% | 12.35% | -2.46% | 6.74% |
| SG&A Expenses | 27.77% | 21.59% | 66.61% | 32.94% | 10.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.71% | 8.41% | 8.98% | 6.53% | -2.85% |
| Operating Income | -2.89% | -1.75% | -4.14% | -9.55% | 2.85% |
| Income Before Tax | -0.09% | 0.15% | -2.22% | -15.29% | -2.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.09% | 0.15% | -2.22% | -15.29% | -2.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.09% | 0.15% | -2.22% | -15.29% | -2.22% |
| EBIT | -2.89% | -1.75% | -4.14% | -9.55% | 2.85% |
| EBITDA | -2.94% | -1.93% | -4.41% | -9.99% | 3.08% |
| EPS Basic | 97.60% | 97.68% | 97.46% | 17.19% | 20.72% |
| Normalized Basic EPS | 97.60% | 97.68% | 97.46% | 17.19% | 20.72% |
| EPS Diluted | 97.60% | 97.68% | 97.46% | 17.19% | 20.72% |
| Normalized Diluted EPS | 97.60% | 97.68% | 97.46% | 17.19% | 20.72% |
| Average Basic Shares Outstanding | 4,068.67% | 4,199.74% | 3,921.92% | 39.21% | 28.93% |
| Average Diluted Shares Outstanding | 4,068.67% | 4,199.74% | 3,921.92% | 39.21% | 28.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |